Picture of Chunghwa Chemical Synthesis & Biotech Co logo

1762 Chunghwa Chemical Synthesis & Biotech Co Share Price

0.000.00%
tw flag iconLast trade - 00:00
HealthcareAdventurousSmall CapNeutral

Momentum

Relative Strength (%)
1m-1.05%
3m-13.48%
6m-23.52%
1yr-46.05%
Volume Change (%)
10d/3m-7.01%
Price vs... (%)
52w High-54%
50d MA-5.52%
200d MA-22.02%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital6.47%
Return on Equity8.1%
Operating Margin13.46%

Financial Summary

Year End 31st DecUnit201920202021202220232024E2025ECAGR / Avg
Total RevenueTWDm1,156.641,543.591,934.72,117.142,086.441,730n/a15.4%
Operating Profitm
Net Profitm
EPS Reported
Diluted Normalised EPS
EPS Growth%+238.83+111.81+61.56+16.11-42.91-21n/an/a
PE Ratiox
PEG
Profitability
Operating Margin%
ROA%
ROCE%
ROE%
Cashflow
Op. Cashflow ps
Capex ps
Free Cashflow ps
Dividends
Dividend ps
Dividend Growth%
Dividend Yield%
Dividend Coverx
Balance Sheet
Cash etcm
Working Capitalm
NFAm
Net Debtm
Book Valuem
Diluted Weighted Average Sharesm
Book Value ps

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202431st Dec 2025
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2024 / 2025

Blurred out image of Chunghwa Chemical Synthesis & Biotech Co EPS forecast chart

Profile Summary

CHUNGHWA CHEMICAL SYNTHESIS & BIOTECH CO., LTD. is a Taiwan-based company principally engaged in the manufacture and distribution of biotechnology products and chemical synthetic products. The Company's biotechnology products include pravastatin, rapamycin, tacrolimus, everolimus, mycophenolate mofetil, mycophenolic acid sodium and others. Its non-biotechnology products include methocarbamol, guaifenesin, trandolapril, fluconazole, olopatadine, dexbromopheniramine maleate and glipizide, among others. Its products are applied in the manufacture of drugs for treatment of cough, diabetes, cardiovascular diseases, high blood pressure and immune system diseases. The Company distributes its products within domestic market and to overseas markets, including the rest of Asia, the Americas and Europe.

Directors

Last Annual
December 31st, 2023
Last Interim
December 31st, 2023
Incorporated
May 19th, 1964
Public Since
December 10th, 2009
No. of Employees
243
Sector
Pharmaceuticals
Industry
Healthcare
Exchange
tw flag iconTaiwan Stock Exchange
Shares in Issue
77,560,000

1762 Share Price Performance

Upcoming Events for 1762

Q1 2024 Chunghwa Chemical Synthesis & Biotech Co Ltd Earnings Release

Q2 2024 Chunghwa Chemical Synthesis & Biotech Co Ltd Earnings Release

Similar to 1762

Picture of Adimmune logo

Adimmune

tw flag iconTaiwan Stock Exchange

Picture of Bora Pharmaceuticals Co logo

Bora Pharmaceuticals Co

tw flag iconTaiwan Stock Exchange

Picture of Formosa Laboratories logo

Formosa Laboratories

tw flag iconTaiwan Stock Exchange

Picture of Lotus Pharmaceutical Co logo

Lotus Pharmaceutical Co

tw flag iconTaiwan Stock Exchange

FAQ